« Back to Farmacia Journal 1/2025

CHARACTERISATION AND VALIDATION OF AN ISOPROTERENOL-INDUCED HEART FAILURE MOUSE MODEL

BIANCA-ȘTEFANIA PROFIRE ¹, FLORENTINA GEANINA LUPAȘCU ², ANDREI SZILAGYI ³, IVONA COSTĂCHESCU ³, BOGDAN-IONEL TAMBA ³, LENUȚA PROFIRE ², IRINA-DRAGA CĂRUNTU ¹, SIMONA-ELIZA GIUȘCĂ ¹, ANDREI TIMOFTE ¹, CRISTIAN STĂTESCU ^1,4, VICTORIȚA ȘORODOC ^1,5, RADU-ANDY SASCĂU ^1,4*, LAURENȚIU ȘORODOC ¹,5

1Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 16 University Street, 700115, Iaşi, România
² Faculty of Pharmacy, “Grigore T. Popa” University of Medicine and Pharmacy, 16 University Street, 700115, Iaşi, România
³ Advanced Research and Development Center for Experimental Medicine “Prof. Ostin C. Mungiu” (CEMEX), “Grigore T. Popa” University of Medicine and Pharmacy, 16 University Street, 700115, Iasi, Romania
⁴ Institute for Cardiovascular Diseases “Prof. Dr. George I.M. Georgescu”, 50 Carol I Boulevard, Iași, Romania
⁵ “Sf. Spiridon” Clinical Emergency Hospital, 1 Independence Boulevard, Iași, Romania

Download Full Article PDF

The objective of this study was to establish and characterise a mouse model of HF using isoproterenol (ISO), a non-selective beta-adrenergic agonist. Different doses of ISO, administered over a variable period (160 mg/kg, 1 day; 80 mg/kg, 5 days; 40 mg/kg, 7 days; and 20 mg/kg, 25 days) were used to obtain a reproducible and robust HF model. Echocardiographic parameters such as left ventricular anterior/posterior wall thickness in diastole/systole (LVAWd, LVAWs, LVPWd, LVPWs), left ventricle internal diameter in diastole/systole (LVIDd, LVIDs), left ventricular end-diastolic/systolic volume (LVEDV, LVESV), fractional shortening (FS), ejection fraction (EF), left ventricular mass (LV mass), relative wall thickness (RWT), stroke volume (SV), as well as histopathological analysis, were used to characterize the HF model. The validated HF mouse model will be used for pharmacological studies of novel therapeutic candidates for HF.